Nabil Lally's tenure at Quotient Sciences is marked by pioneering the Translational Pharmaceutics platform, delivering an average of 12 months in timeline savings and substantial R&D cost reductions. This integrative strategy has not only streamlined the development process but has also enabled a more efficient path to commercialization, ensuring our clients' success and solidifying our position as industry leaders in drug development acceleration.

Nabil holds a degree in Biology from University of South Carolina and Masters in Biotechnology/Bioscience from The Johns Hopkins University.